Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)

Fikri Icli; Hakan Akbulut; Handan Onur; Bulent Yalcin; Ahmet Demirkazık; Filiz Çay Senler

doi:10.1016/j.breast.2010.09.002

Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)

Breast. 2011 Apr;20(2):155-7. doi: 10.1016/j.breast.2010.09.002. Epub 2010 Oct 15.

Authors

Fikri Icli¹, Hakan Akbulut, Handan Onur, Bulent Yalcin, Ahmet Demirkazık, Filiz Çay Senler

Affiliation

¹ Ankara University School of Medicine, Dept. of Medical Oncology, Dikimevi, 06590 Ankara, Turkey. [email protected]

PMID: 20951586
DOI: 10.1016/j.breast.2010.09.002

Abstract

Background and objectives: Previous reports suggest that including cisplatin plus etoposide in the adjuvant treatment may improve the outcomes in patients with early breast cancer.

Patients and methods: Forty-one patients with early breast cancer and 4 or more positive lymph nodes were treated with 3 cycles of EoP (oral etoposide plus cisplatin) in addition to 3 cycles of AC (doxorubicin plus cyclophosphamide) and 3 cycles of T (docetaxel) (Group 1). Toxicity and survival results were compared to those with similar disease characteristics who were treated with 4 cycles of AC plus 4 cycles of T (Group 2) during the same period.

Results: There were no long-term side effects related to EoP. While median disease-free and overall survivals were not reached in Group 1, they were 107 ± 13 (p = 0.387) months and 123 ± 5 months (p = 0.618) in Group 2. Likewise 10-year disease-free survivals (DFS) were 59.3% and 44.7% respectively.

Conclusions: The trend towards improvement in survival with adjuvant AC + T + EoP when compared to AC + T needs to be studied in randomized trial.

Publication types

Comparative Study

MeSH terms

Administration, Oral
Antibiotics, Antineoplastic / administration & dosage
Antibiotics, Antineoplastic / therapeutic use
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Antineoplastic Agents, Alkylating / administration & dosage
Antineoplastic Agents, Alkylating / therapeutic use
Antineoplastic Agents, Phytogenic / administration & dosage
Antineoplastic Agents, Phytogenic / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Breast Neoplasms / radiotherapy
Chemotherapy, Adjuvant
Cisplatin / administration & dosage
Cisplatin / therapeutic use*
Cyclophosphamide / administration & dosage
Cyclophosphamide / therapeutic use*
Disease-Free Survival
Docetaxel
Doxorubicin / administration & dosage
Doxorubicin / therapeutic use*
Drug Administration Schedule
Etoposide / administration & dosage
Etoposide / therapeutic use*
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Lymphatic Metastasis
Middle Aged
Pilot Projects
Taxoids / administration & dosage
Taxoids / therapeutic use*

Substances

Antibiotics, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Taxoids
Docetaxel
Etoposide
Doxorubicin
Cyclophosphamide
Cisplatin